Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of SSGJ-707 in advanced non-small cell lung cancer
CTR20241649Phase 2Active
- Sponsor
- 3SBio
- Start
- Jul 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of PF-08634404 in non-small cell lung cancer (NSCLC), sponsored by 3SBio. Started Jul 2024; status: active.
02
Drugs
PF-08634404
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20241649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241649.